Sonoma Pharmaceuticals In... (SNOA)
| Bid | 2.3 |
| Market Cap | 3.82M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.26 |
| PE Ratio (ttm) | -1.05 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 2.63 |
| Volume | 29,356 |
| Avg. Volume (20D) | 143,083 |
| Open | 2.45 |
| Previous Close | 2.47 |
| Day's Range | 2.30 - 2.47 |
| 52-Week Range | 2.30 - 9.40 |
| Beta | undefined |
About SNOA
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; ...
Analyst Forecast
According to 1 analyst ratings, the average rating for SNOA stock is "Buy." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago · accessnewswire.com
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2025 Financial ResultsRevenues increased 14% for the quarter compared to prior year and 13% year-to-date Positive cash flow from operations for the quarter with $5.2 million of cash at December 31, 2024 Year-to-date net lo...
